Unfortunately, I don't take their word for it. I remember a shareholder meeting where Stoll stated that the problems with CX-717 had been laid to rest, and on the strength of that share price rose steeply... except that the FDA didn't buy it.
Even if Varney is being truthful that cx-1739 meets the tox standards that cx-717 failed to meet, and even though Laughren supposedly told Stoll that if corx brought them a compound that met all of the tox standards that were set for cx-717, he would approve the IND, I'm not counting on anything; the process is too opaque and arbitrary.
That said, I'm more confident about the IND than I am about the SA trial. I also think the IND is more important: if the approval comes through, the FDA will have given the green light for a trial using an ampakine for an indication requiring chronic use. If we get that approval, whether or not the drug shows efficacy in ADHD (I'm pretty confident about that too, since I think low impacts will act generically as cognitive enhancers), this approval will remove the taint associated with ampakines since the cx-717 debacle.
Market Data 
Markets 
AI
